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A proform of high molecular weight type IV collagenase was isolated and purified 1230-fold from human metastatic arcinoma tissue. Like matrix 
metalloproteinases (MMPs), the enzyme was activated by trypsin and degraded type IV collagen and gelatin at a neutral pH, the activity was 
inhibited by EDTA and o-phenanthroline. However, the molecular weight was much higher than MMPs which degraded type IV collagen, gelatinase 
A (MMP-2; 72 kDa gelatinase/type IV collagenase) (EC 3.4.24.24) gelatinase B (MMP-9; 92 kDa gelatinase/type IV collagenase) (EC 3.4.24.35), 
stromelysin-1 (MMP-3; 57 kDa) (EC 3.4.24.17) and stromelysin-2 (MMP-IO; 57 kDa) (EC 3.4.24.22). The other significant difference from MMPs 
was that the enzyme was not activated by 4-aminophenylmercuric a etate nor inhibited by TIMP. Taking together these results, this high molecular 
weight type IV collagenase might be a newly found enzyme different from MMPs or might have the same configuration as MMPs already reported. 
High molecular weight type IV collagenase; Type IV collagenase; Metastatic carcinoma tissue 
1. INTRODUCTION 
Type IV collagen is one of the major structural pro- 
teins in basement membrane of the extracellular matrix 
(ECM). Since the synthesis, assembly and turnover of 
ECM seem to be controlled to maintain normal tissue 
functions, abnormal turnover in collagen matrices 
would be associated with disease states such as tumor 
invasion, rheumatoid arthritis and osteoarthritis [l-3]. 
On the other hand, the matrix metalloproteinases 
(MMPs) are a group of 8 proteinases degrading the 
major components of matrices at neutral pH, and it is 
noted that they play some role in the process of invasion 
and metastasis of cancer cells [4-61. Four of 8 MMPs 
degrading type IV collagen are termed MMP-2 (gelati- 
nase A, 72 kDa collagenase) (EC 3.4.24.24), MMP-9 
(gelatinase B, 92 kDa collagenase) (EC 3.4.24.35), 
MMP-3 (stromelysin-1, EC 3.4.24.17) and MMP-10 
(stromelysin-2, EC 3.4.24.22) [7-121. Correlation be- 
tween metastatic potential and regulation of MMPs 
activation, especially MMP-2 and MMP-9 has been elu- 
cidated recently [13,14], and almost all MMPs so far 
Correspondence address. T.T. Tsuda, Molecular Life Science, School 
of Medicine, Tokai University, Bohseidai, Isehara, Kanagawa 259-I 1, 
Japan. Fax: (81) (463) 96-4828. 
Abbrevrations: APMA, 4-aminophenylmercuric a etate; DTT, dithio- 
threitol; ECM, extracellular matrix; EDTA, ethylenediamine- 
tetraacetic acid; HPLC, high performance liquid chromatography; 
MMPs, matrix metalloproteinases; PAGE, polyacrylamide gel elec- 
trophoresis; PMSF, phenylmethylsulfonyl fluoride; SDS, sodium do- 
decyl sulfate; TIMP, tissue inhibitor of metalloproteinases. 
characterized have been isolated from culture medium 
secreted by various cell lines [7-141. We have found and 
purified a high molecular weight type IV collagenase 
from tissue of metastatic liver carcinoma and compared 
its properties to the previously reported MMPs. 
2. MATERIALS AND METHODS 
2.1. Enzyme purification 
The enzyme was purified by a slight modification of the previously 
described method [15]. 70 g of carcinoma tissue were homogenized 
with 5-fold volumes of 50 mM Tris-HCI buffer, pH 7.6, containing 520 
mM NaCl and 5 mM CaCl,, and sonicated. The preparation was 
centrifuged at 12,000 rpm (15,000 xg) for 20 min to obtain crude 
extract. Protein was precipitated from 25% to 5S% saturated ammo- 
nium sulfate. The precipitate was dissolved at 10 mg/ml in 50 mM 
Tris-HCl buffer, pH 7.6, and purified further by DEAE-cellulose col- 
umn and hydroxyapatite column chromatography and finally by Se- 
phacryl S300 HR column chromatography equilibrated with 50 mM 
Tris-HCl buffer, pH 7.6, containing 20 mM NaCl and 5 mM CaCI,. 
2.2. Enzyme assay 
2.2.1. ‘H-labeled type IV collagenolytic activity 
Type IV collagen from human placenta was purchased from Sigma 
(St. Louis, USA) and ‘H-labeled type IV collagen was prepared as 
described previously by Tsuda et al. [15]. Specific activity of 3H- 
labeled type IV collagen was 330 kBq/mg protein. Enzyme was acti- 
vated with trypsin (17 fig/ml) treatment at 37°C for 10 mitt, trypsin 
digestion was stopped with aprotinin and soybean trypsin inhibitor 
prior to the addition of substrate. Then 6.0 pg of ‘H-labeled type IV 
collagen (2 kBq) was added as a substrate. The reaction mixture (500 
~1) was incubated for 17 h at 37°C. The reaction was stopped and the 
residual substrate was precipitated by the addition of 100 ~1 of 10% 
trichloroacetic acid (TCA) and 5% tannic acid. Collagenolytic activity 
was measured as radioactivity of the TCA supematant. 
One unit was expressed as the amount of enzyme that was capable 
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of solubilizing 1000 cpm of radioactivity into the TCA soluble fraction 
for 17 h at 37°C. 
2.2.2. ‘H-labeled gelatinolytic activity 
‘H-labeled gelatin was obtained by heat denaturing of 3H-labeled 
type IV collagen at 60°C for 30 min. The assay procedure was the same 
as that described above. 
2.3. Inhibition test 
Assays were performed at pH 7.6 in 50 mM Tris-HCI buffer con- 
taining 20 mM NaCl and 5 mM CaCI, using trypsm activated enzyme. 
All commercial inhibitors were purchased from Sigma (St. Louis, MO, 
USA), except for leupeptin, pepstatin and E64. which were from the 
Peptide Institute (Osaka, Japan). Tissue inhibitor of metallopro- 
teinases (TIMP) was kindly supplied from Dr. Gen Kawano, Toray 
Inc. (Tokyo, Japan). 
2.4. 4-Aminophenylmercuric acetate (APMA) activation 
The enzyme preparation was incubated for 2 h at 37°C in the 
presence of 1 mM APMA prior to the addition of ‘H-labeled type IV 
collagen as a substrate. After 17 h incubation collagenolytic activity 
of enzyme was measured as radioactivity (cpm) of the TCA superna- 
tant. 
2.5. Zymography 
Substrate gels (zymogram) were used to examine the gelatm degrad- 
mg species. 1.0 mg/ml of gelatin (Merck, Darmstadt, Germany) was 
incorporated into non-reducing SDS-polyacrylamide 7.5% gels. After 
electrophoresis at 0.8 mA/cm for 3 h at 6°C SDS was removed with 
2.5% Triton X-100 prior to incubation for 17 h at 37°C in 50 mM 
Tris-HCI, pH 7.6, buffer containing 20 mM NaCl and 5 mM CaCl,. 
After enzyme reaction the gels were stained with Coomassie blue and 
destained with 30% methanol and 10% acetic acid in distilled water. 
Gelatinolytic enzyme was detected as transparent bands on the blue 
background of stained gel containing gelatm. 
2.6. Protein determmation 
The protein concentration was estimated by Lowry method [16]. 
2.7. Gelfiltratron HPLC 
Approximately 2 mg of partially purified enzyme were applied to 
a 10 mm x 30 cm prepacked column of Superose 6 HR (Pharmacia. 
Milwaukee, USA) equilibrated with 50 mM Tris-HCI, pH 7.6, buffer 
containing 20 mM NaCI. 5 mM CaClz and 0.05% Brij-35. The flow 
rate was maintained at 0.3 ml/min, and the fractions (0.3 ml) were 
collected. Absorbance was recorded at 280 nm. Enzyme activity was 
assayed using 100 ~1 of each fraction. Molecular weight markers were: 
thyroglobulin (670 kDa), y-globulin (158 kDa), ovalbumin (44 kDa), 
myoglobm (17 kDa) and cyanocobalamin (1.35 kDa). 
2.8. Estimcrtron of the molecular weight after trypsin treatment 
Three mg of purified enzyme were treated with trypsin at 37°C for 
10 min and applied to a Sephacryl S300 HR column equilibrated with 
50 mM Tris-HCl buffer, pH 7.6, containing 20 mM NaCl and 5 mM 
CaC&. Absorbance at 280 nm and type IV collagenolytic activity were 
measured in each tube. 
3. RESULTS 
3.1. Enzyme purification 
A latent form of high molecular weight type IV col- 
lagenase was purified from solid metastatic liver carci- 
noma from rectal adenocarcinoma. A typical purifica- 
tion procedure was summarized in Table I, with final 
purification by Sephacryl S300 column chromatogra- 
phy calculated to be 1,230-fold (Table I). High molecu- 
lar weight type IV collagenase was eluted in the 1 st peak 
that was fraction 1 in Fig. 1A. 
Eight cases of metastatic liver carcinoma were exam- 
ined by the same procedure described here, and the 
enzyme was detected in 3 cases in which primary lesion 
was rectal adenocarcinoma. The enzyme was purified 
from them by the same procedure as described above. 
3.2. Activation 
The purified high molecular weight collagenase was 
inactive. It was activated only by trypsin and not by 1 
mM or 2 mM APMA (Table II), indicating that the 
enzyme was present as a latent form and that it required 
activation. 
3.3. Molecular weight 
The molecular weight was estimated to be over 2,000 
kDa given by Sephacryl S300 HR column chromatogra- 
phy (Fig. 1A) and confirmed by Superose 6 HR HPLC. 
Addition of non-ionic detergent such as Brij-35 caused 
no change in molecular weight. The purified enzyme 
obtained as the 1st peak of Sephacryl S300 column 
chromatography (Fig. 1A) was re-chromatographed 
and eluted again at the same position as eluted before. 
Trypsin treatment gave no difference in elution pattern 
of Sephacryl S300 HR column chromatography (Fig. 2) 
nor produced any smaller enzyme including 95 kDa 
gelatinase. 
Table I 
Purification of high molecular weight type IV collagenase 
Purification step 
Crude extract 
Amm. Std. ppt. 
DEAE-cellulose 
Hydroxyapatite 
Sephacryl S300 HR 
column chromatography 
Total protein Total activity 
(mg) (U) 
3196 11,550 
1009 3196 
99 9884 
29 5140 
0.45 1955 
Specific activity Relative purification Recovery 
(U/mg prot.) (fold) (%) 
3.6 1 100 
3.2 0.9 28 
100 28 86 
176 49 45 
4433 1231 17 
Starting material was 70 g of metastatic liver carcinoma tissue. One unit was expressed as ‘H-labeled type IV collagenolytic activity that was capable 
of solubilizing 1000 cpm of the radioactivity into TCA soluble fraction. 
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Fig. 1. (A) SephacrylS300 column chromatography of high molecular 
weight type IV collagenase. 14 mg of partially purified enzyme in 2 ml 
were applied to a column of Sephacryl S300 BR equilibrated with 50 
mM Tris-HCl, pH 7.6, buffer containing 20 mM NaCl and 5 mM 
CaCl,. Column size was 2.5 x 90 cm, flow rate was 45 ml/60 mm and 
2.4 ml of tubes were collected. Absorbance at 280 nm (0) and ‘H- 
labeled type IV colla~nolytjc activity (r) was measured. Each 10 
tubes (30 ml) was concentrated by Centricut 10 (Kurabou, Osaka, 
Japan) to 2 ml, cited fraction number from I to 7. Molecular weight 
markers were bIue dextran (void volume), imtnuno~obui~n M (900 
kDa), ferritin (450 kDa), bovine serum albumin (68 kDa) and pyri- 
doxal phosphate (0.3 k.Da). (B) Pattern of zymography, before and 
after Sephacryl S300 HR column chromatography. Left: before col- 
umn chromatography. Applied volume was 4 ,ul per lane. Molecular 
weight of the gelatinolytic enzyme observed as a transparent band was 
95 kDa. Right: after column chromatography. Fractions t to 7 of 
column chromatograph~~ shown in Fig. Ipi, were applied onto lane 
1 to 7. Applied volume was 4 ~1 per lane. Procedure of zymography 
was described in section 2. MolecuIar weight markers were myosin 
(212 kDa), c+macroglobulin (170 kDa), p-galactosidase (116 kDa), 
transferrm (76 kDa) and glutamic dehydrogenase (53 kDa). Note that 
the transparent band was not detected in the lane 1 (fraction 1 in Fig. 
1A) or 2 (fraction 2 in Fig. lA), though a significant band was ob- 
served in lane 3 and 4. The molecular weight of the gelatinolytlc 
enzyme was 95 kDa. The gelatinolytic activity can be compared be- 
tween left and right q~~~t~tat~vely, since2 ml of sample was Fraction- 
ated into 7 fractions from 1 to 7, ciied in Fig. 1 A. then the volume of 
each fraction was con~ntrated to 2 ml. 
3.4. Detection of activity of high molecular weight type 
IV collagenase 
3H-labeled substance degrading activity of both type 
IV collagen and gelatin were apparently found in this 
enzyme. Zymography was not adequate for this detec- 
tion, because no transparent band was obtained even 
with the activated enzyme. 
3.5, reparation ofhigh molecular weight type IV collage- 
nase from 95 kDa geiatinase 
The radiological and zymographic analyses revealed 
that the partially purified enzyme before applied to Se- 
phacryl S300 column chromatography contained type 
IV collagenase activity as well as a low molecular weight 
enzyme (95 kDa gelatinase) which was shown on zy- 
mography (Fig. lB, left column). The high molecular 
weight type IV collagenase was separated from 95 kI3a 
gelatinase by Sephacryl 5300 column chromatography. 
The purified enzyme (fraction 1 in Fig. lA), showed 
high 3H-labeled type IV collagen degrading activity, but 
no gelatinolytic activity was shown on zymography 
(Fig. 13, lane 1 in right column). 
3.6. I~~i~it~~n by TIMP crncd others 
As shown in Table III, the activity of the high molec- 
ular weight type IV collagenase was inhibited by metal 
chelators such as EDTA and o-phenanthroline, but not 
other seryl or thiol protease inhibitors, indicating that 
the enzyme was a metalloproteinase. In addition the 
enzyme activity was inhibited by reducing agents. 
It was noted that TIMP, an endogeneous inhibitor of 
MMPs. was totally ineffective. 
4. DISCUSSION 
Following the previous reports on a type IV collage- 
nase with high molecular mass which was isolated from 
human stomach carcinoma [15,17], the present study 
indicates that a high molecular weight type IV collage- 
nase activity has been observed in 3 out of 8 different 
cases of metastatic liver carcinoma examined. Also, this 
enzyme activity was found in 2 cases of S hepatocellular 
carcinoma, but not in noncancerous liver tissues. 
We have described further characterization of this 
purified high molecular weight type IV collagenase and 
compared its properties with the previously reported 
MMPs, which are to some extent in common; the en- 
Table II 
Activation by trypsin and APMA 
High M.W. type IV 95 l&a gelatinase 
callagenase activity activity 
(cpm) (ccpm) 
No addition 486 177 
APMA 809 2142 
frypsin 5195 2403 
High molecular weight type IV collagenase (1.1 pug) and 95 kDa en- 
zyme (3 pg) were incubated with APMA (1 mM) at 37°C for 2 h or 
with trypsin (17 pg/ml) at 37°C for 10 min, respectively. 3H-labeled 
type IV collagenolytic activity was measured, 
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Fig. 2. Sephacryl S300 column chromatography of trypsin treated high 
molecular weight type IV collagenase. Purified high molecular weight 
type IV collagenase, shown as fr. 1 in Fig. 1 A, was treated by trypsm 
at 37°C for 10 min and applied to a Sephacryl S300 HR column. The 
running conditions were the same as in Fig. IA. 
zyme is activated by trypsin, degrading type IV collagen 
and gelatin, and is inhibited by metal chelators such as 
EDTA and o-phenanthroline as well as reducing agents 
[18]. However, in view of the molecular size and mode 
of activation and inhibition, the enzyme described here 
is definitely different from the MMPs. The molecular 
weight of this enzyme is estimated to be over 2,000 kDa, 
which is not identical to any one of the MMPs family 
nor some other similar enzymes such as heterodimer of 
MMP-9 (215 kDa) [19] and a matrix metalloproteinase 
(700 kDa) [20]. In addition, the high molecular weight 
type IV collagenase is neither activated by APMA, a 
general activator of MMPs, nor inhibited by TIMP 
which will form a stable stoichiometric complex with 
MMP-9 and MMP-2, namely, TIMP and TIMP-2, re- 
spectively [21,22], although a few reports are available 
as to TIMP resistant matrix metalloproteinase having 
the molecular weight of 700 kDa [20]. 
It should be noted that the MMPs isolated and char- 
acterized are mostly from the cultured medium of vari- 
ous cell lines, and in this experiment, the enzyme purifi- 
cation has been carried out by using tissues from solid 
carcinoma. Despite the sensitive zymographic analysis, 
on which MMPs can be detected, neither the active nor 
latent form of the high molecular weight type IV col- 
lagenase was found, even though 3H-labeled collagen 
and gelatin degrading activities were noted. This may 
be due to the immobility of the high molecular weight 
enzyme on SDS-PAGE. 
On zymography, 95 kDa gelatinase has been found 
in all the samples examined including 8 cases of metas- 
tatic liver carcinoma, 5 cases of hepatocellular carci- 
noma and 4 cases of noncancerous liver tissues. The 
properties of this 95 kDa enzyme partially purified are 
very similar to those of the ordinary MMPs. This 95 
kDa enzyme is activated by both APMA and trypsin 
with a fall in molecular weight. There is a possibility 
that the 95 kDa enzyme forms complexes with TIMP-1 
and that the complex can be activated to give active 
enzyme. The activity of this enzyme is inhibited by 
EDTA and o-phenanthroline, but not by seryl or thiol 
proteinase inhibitors. From these results and its molec- 
ular weight, 95 kDa gelatinase detected here would be 
gelatinase B (MMP-9,92 kDa type IV collagenase, EC 
3.4.24.35). 
It has been reported that high expression of gelatinase 
B (MMP-9) is associated with oncogene transformation 
[8,23], and a good correlation is found between this 
enzyme activity and the metastatic potential of several 
types of tumors [23-281. Although the physiological sig- 
nificance of this high molecular weight type IV collage- 
nase remains unclear, the enzyme may play some role 
Table III 
Effect of inhibitors on high molecular weight type IV collagenase 
activity 
Inhibitor Concentration Inhibition (%) 
EDTA 5mM 99 
10 mM 100 
o-Phenanthroline 5mM 99 
10 mM 99 
Leupeptin 5 @ml 0 
10 &ml 0 
Pepstatin 5 &ml 0 
10 @ml 0 
E-64 5 fig/ml 0 
10 pg/rnl 0 
PMSF 5mM 0 
10 mM 0 
TIMP 1.1 @ml 0 
5.3 &ml 0 
10.6 &ml 0 
21.3 pg/ml 0 
2-Mercaptoethanol 5mM 88 
10 mM 95 
DTT 5mM 93 
10 mM 94 
Human serum 4% 76 
8% 92 
High molecular weight type IV collagenase was activated by trypsin 
prior to addition of inhibitors and ‘H-labeled substrate. Then enzyme 
reaction was performed at 37°C for 17 h. 
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in cancer metastasis, because significantly high activity 
has been noted in 3 out of 8 metastatic ases (601 units/g 
tissue, 523 units/g tissue, 323 units/g tissue, respec- 
tively), and no activity has been detected in noncancer- 
ous liver tissue (n = 4). Further studies on the relative 
quantity of this enzyme and ubiquitous inhibitors and 
histological localization in various carcinoma tissues 
will be needed to elucidate the pathophysiological sig- 
nificance as well as the metastatic ability of tumor cells. 
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